Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)

Alzheimer Disease Clinical Trial

— CASL  

Official title:

Semantic Memory, Financial Capacity and Brain Perfusion in MCI

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00880555
• Other study ID #: E6553-W
• Status: Completed
• Phase: N/A
• First received: April 10, 2009
• Last updated: May 15, 2015
• Start date: April 2009
• Est. completion date: May 2014

Study information

• Verified date: May 2015
• Source: VA Office of Research and Development
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Observational

Clinical Trial Summary

Alzheimer's disease often manifests as a memory disorder before dementia develops. Dementia is considered to be present when a person can no longer handle complex activities of daily living, such as managing finances. This study will investigate the relationship between changes in the ability to manage finances and brain perfusion, which will be measured using continuous arterial spin-labeling (an experimental MRI). Subjects will also undergo neuropsychological tests focusing on several types of memory and thought process, with special emphasis on semantic memory. An important question to be addressed is whether changes in function are better predicted by the neuropsychological tests or by the brain scan.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 160
• Est. completion date: May 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 50 Years to 89 Years

Eligibility

Inclusion Criteria:

• Veteran or non-veteran

• Age 50-89

• With normal cognition or memory impairment (MCI or mild AD)

• English speaking

• Right handed

• Adequate vision and hearing to take part in tests

• Able and willing to undergo MRI scan

• Medically and psychiatrically stable

• No other brain disease (such as tumor, Parkinson's disease, major stroke)

Exclusion Criteria:

• Pregnancy

• Inability to tolerate MRI (due to metal in body or claustrophobia)

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Alzheimer Disease
• Cognition Disorders
• Dementia
• Mild Cognitive Impairment

Locations

Country	Name	City	State
United States	Birmingham VA Medical Center, Birmingham, AL	Birmingham	South Carolina

Sponsors (2)

Lead Sponsor	Collaborator
VA Office of Research and Development	University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

References & Publications (3)

Clark DG, Kapur P, Geldmacher DS, Brockington JC, Harrell L, DeRamus TP, Blanton PD, Lokken K, Nicholas AP, Marson DC. Latent information in fluency lists predicts functional decline in persons at risk for Alzheimer disease. Cortex. 2014 Jun;55:202-18. do — View Citation

Clark DG, Wadley VG, Kapur P, DeRamus TP, Singletary B, Nicholas AP, Blanton PD, Lokken K, Deshpande H, Marson D, Deutsch G. Lexical factors and cerebral regions influencing verbal fluency performance in MCI. Neuropsychologia. 2014 Feb;54:98-111. doi: 10. — View Citation

Clark DG; Alzheimer Disease Neuroimaging Initiative. Residual vectors for Alzheimer disease diagnosis and prognostication. Brain Behav. 2011 Nov;1(2):142-52. doi: 10.1002/brb3.19. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in financial capacity (measured with Financial Capacity Instrument)		1-5 years	No